Endometrioid endometrial carcinoma with atrophic endometrium and poor prognosis

Obstetrics and Gynecology

Volumn 120, Issue 5, 2012, Pages 1124-1131

  Geels, Yvette P ^a,b,c,d   Pijnenborg, Johanna M A ^a,b,c,d   Van Den Berg Van Erp, Saskia H ^a,b,c,d   Bulten, Johan ^a,b,c,d   Visscher, Daniel W ^a,b,c,d   Dowdy, Sean C ^a,b,c,d   Massuger, Leon F A G ^a,b,c,d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CPRLab   (Netherlands)

^c CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; ASCITES FLUID CYTOLOGY; BODY MASS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM ATROPHY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ATROPHY; CARCINOMA, ENDOMETRIOID; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE;

EID: 84868159212     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31825bc3b4     Document Type: Article

References (27)

1. American Cancer Society. Global cancer facts & figures. 2008. Available at: www.cancer.org/acs/groups/content/@epidemiology surveilance/documents/document/acspc-027766.pdf. Retrieved January 15, 2012.
2. American Cancer Society. Cancer facts & figures. 2010. Available at: www.cancer.org/acs/groups/content/@nho/documents/document/acspc-024113.pdf. Retrieved January 15, 2012.
3. Bokhman JV. Two pathogenetic types of endometrial carci noma. Gynecol Oncol 1983;15:10-7.
4. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995;26:1268-74.
5. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000;13:295-308.
6. Ellenson HL, Ronnett BM, Kurman RJ. Precursor lesions of endometrial carcinoma. In: Kurman RJ, Ellenson HL, Ronnett BM, editors. Blaustein's pathology of the female genital tract. 6th ed. New York (NY): Springer; 2011. p. 359-91.
7. Ellenson HL, Ronnett BM, Soslow RA, Zaino RJ, Kurman RJ. Endometrial carcinoma. In: Kurman RJ, Ronnett BM, Ellen son HL, editors. Blaustein's pathology of the female genital tract. 6th ed. New York (NY): Springer; 2011. p. 393-452.
8. Markova I, Pilka R, Duskova M, Zapletalova J, Kudela M. Prognostic significance of clinic pathological and selected immunohistochemical factors in endometrial cancer [in Czech]. Ceska Gynekol 2010;75:193-9.
9. Prat J, Gallardo A, Cuatrecasas M, Catasus L. Endometrial carcinoma: pathology and genetics. Pathology 2007;39:72-87.
10. Engelsen IB, Akslen LA, Salvesen HB. Biologic markers in endometrial cancer treatment. APMIS 2009; 117:693-707.
11. Lax SF. Molecular genetic changes in epithelial, stromal and mixed neoplasms of the endometrium. Pathology 2007;39: 46-54.
12. Sivridis E, Fox H, Buckley CH. Endometrial carcinoma: two or three entities? Int J Gynecol Cancer 1998;8:183-8.
13. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103-4.
14. Silverberg SG, Mutter GL, Kurman RJ, Kubik-Huch RA, Nogales F, Tavassoli FA. Tumors of the uterine corpus: epithelial tumors and related lesions. In: Tavassoli FA, Stratton FR, editors. WHO classification of tumors: pathology and genetics of tumors of the breast and female genital organs. 5th ed. Geneva (Switzerland): World Health Organization; 2003. p. 221-32.
15. Mills AM, Longacre TA. Endometrial hyperplasia. Semin Diagn Pathol 2010;27:199-214.
16. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of 'untreated' hyperplasia in 170 patients. Cancer 1985;56:403-12.
17. McCluggage WG. Benign Diseases of the Endometrium. In: Kurman RJ, Ellenson LH, Ronnett BM, editors. Blaustein's pathology of the female genital tract. 6th ed: New York (NY): Springer; 2011. p. 305-58.
18. Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO, et al. Prospective assessment of lymphatic dissem ination in endometrial cancer: a paradigm shift in surgical staging. Gynecol Oncol 2008;109:11-8.
19. Oncoline: cancer clinical practice guidelines. Available at: www.oncoline.nl. 2011. Retrieved January 15, 2012.
20. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, van den Bergh AC, de Winter KA, Koper PC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 2004;22: 1234-41.
21. Fujimoto T, Nanjyo H, Fukuda J, Nakamura A, Mizunuma H, Yaegashi N, et al. Endometrioid uterine cancer: histopathological risk factors of local and distant recurrence. Gynecol Oncol 2009;112:342-7.
22. Halperin R, Zehavi S, Habler L, Hadas E, Bukovsky I, Schneider D. Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium. Eur J Gynaecol Oncol 2001;22:122-6.
23. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000;15:88: 814-24.
24. Voss MA, Ganesan R, Ludeman L, McCarthy K, Gornall R, Schaller G, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation. Gynecol Oncol 2012;124:15-20.
25. Kurman RJ, McConnell TG. Precursors of endometrial and ovarian carcinoma. Virchows Arch 2010;456:l-12.
26. Gol K, Saracoglu F, Ekici A, Sahin I. Endometrial patterns and endocrinologic characteristics of asymptomatic menopausal women. Gynecol Endocrinol 2001;15:63-7.
27. Sivridis E, Giatromanolaki A. Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma. J Clin Pathol 2004;57: 840-4.